RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today released a summary of its 2008
financial results. Total sales were virtually flat at $1,101,991 in 2008
compared to $1,104,325 in 2007. The pharmaceutical business sales for 2008, grew
by 185% off a small base, from $60,239 in 2007 to $171,948 in 2008. The
bio-friendly insecticide business sales decreased by 10.9% from $1,044,086 in
2007 to $930,043 in 2008.


Gross margins decreased from 68.9% in 2007, to 58.8% in 2008 primarily because
of a sales mix in favour of lower margin products.


The Company incurred a loss of ($287,892) in 2008 compared to a loss of
($125,991) in 2007. This loss is predominantly due to higher pharmaceutical
operating expenses for the establishment of the hospital division and the launch
of Ciprofloxacin Injection, which was first shipped in May 2008.


Total negative cash flow for 2008 was ($295,260) versus a positive cash flow of
$27,566 in the prior year period. This was due to the cash loss during the year
and investment in new computer systems to support future business growth.


Full details of 2008 results including December 31, 2008 Financial Statements
and Management's Discussion & Analysis will be published in the company's 2008
Annual Report and will be posted on sedar.com on April 24, 2008.


BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada.
These pharmaceuticals will compete in both the branded and generic market
segments and will not require further product development investment other than
regulatory costs.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX.


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2023 to Jul 2024